Physician profile
Ramadevi Devabhaktuni
NPI 1891789558
$3,118.75
in general payments reported to CMS, 2019-2025
33 companies · $899 in 2025
The $899 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $212 · 2020: $68.96 · 2021: $330 · 2022: $328 · 2023: $651 · 2024: $631 · 2025: $899.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,179.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $310.47 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $288.03 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $285.37 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $270.56 | 2022-2025 | |
| Glaxosmithkline, LLC. | $254.46 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $217.62 | 2020-2025 | Evenity, Prolia, Repatha |
| Abbott Laboratories | $186.56 | 2021-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $181.22 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $161.36 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.83 | 2021-2025 | Jardiance, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $124.21 | 2021-2025 | |
| Mylan Specialty L.P. | $103.06 | 2023-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $90.86 | 2021-2025 | |
| Dexcom, INC. | $47.76 | 2021-2024 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $45.00 | 2020-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $41.46 | 2021-2025 | |
| Axsome Therapeutics, INC. | $39.15 | 2023-2025 | Auvelity |
| Nevro Corp. | $33.36 | 2022 | |
| Neurelis, INC. | $32.90 | 2023 | Valtoco |
| Otsuka America Pharmaceutical, INC. | $29.17 | 2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $25.75 | 2023 | |
| Xeris Pharmaceuticals, INC. | $24.19 | 2025 | Gvoke Hypopen |
| Optinose US, INC. | $23.94 | 2021 | |
| Biotronik Nro, INC. | $20.69 | 2025 | Prospera |
| Sumitomo Pharma America, INC. | $19.40 | 2025 | Gemtesa |
| Hologic Sales and Service, LLC | $18.37 | 2024 | Third Wave, Thinprep 2000 Processor, Aptima |
| Sunovion Pharmaceuticals INC. | $18.25 | 2021 | |
| Astellas Pharma US INC | $18.17 | 2023 | Veozah |
| Abbvie INC. | $17.65 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $16.65 | 2025 | Zoryve |
| Biohaven Pharmaceutical Holding Company Ltd. | $15.64 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.51 | 2022 | |
| Sanofi Pasteur INC. | $14.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramadevi Devabhaktuni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.